Ed Shovelin: PDE Inhibitors Preferentially Affect ADP and TRAP6 Activation
Ed Shovelin, Operations and Engineering Manager at Pplus Medical Limited, shared on LinkedIn:
”CRP-A by Pplus Medical Limited is increasingly becoming a trusted platelet activator for leading researchers around the world, and we’re delighted to highlight the innovative work it helps make possible.
This week we want to share the following work by Professor Gawaz and his team at the Hospital of the University of Tübingen: Effect of phosphodiesterase inhibitors on platelet function.
Hypothesis: PDE2, PDE3 and PDE5 display differential effects on platelet-mediated thrombosis.
Methods: Compare the effects of PDE inhibition by Ibudilast, a non-selective inhibitor of several PDEs with preference towards PDE3, PDE4, PDE10 and PDE11, IBMX, a nonspecific PDE inhibitor and Sildenafil, a potent selective PDE5 inhibitor, respectively, on platelet activation, aggregation and thrombus formation.
How CRP-A was used: CRP-A was used to induce GPVI-mediated platelet activation, aggregation and thrombus formation.
Key Findings: Platelet activation by ADP via P2Y12 and TRAP6 via PAR1 showed a greater response to PDE inhibitors than platelet activation by CRP-A via GPVI”
Title: Effect of phosphodiesterase inhibitors on platelet function
Authors: Ravi Hochuli, Valerie Dicenta, Zoi Laspa, Manuel Sigle, Tobias Harm, Tatsiana Castor, Anne-Katrin Rohlfing, Meinrad Paul Gawaz
Read the Full Article on Biochemistry and Biophysics Reports

Stay updated on all scientific advances with Hemostasis Today.
-
Nov 18, 2026, 13:06Saurabh Mehta: Daily Iron Supplementation in Children and Adolescents
-
Nov 18, 2026, 12:46Thirunavukkarasu Angappan: Fibrinogen in Postpartum Haemorrhage
-
Nov 18, 2026, 01:45Shikha Jha: My Takeaways from the 4th GANSID International Congress
-
Nov 18, 2026, 01:34Zeeshan Ahmed Khattak: Treatment of Fever and Neutropenia in Hematology/Oncology and Hematopoietic Cell Transplant Patients
-
Nov 17, 2026, 23:45Cajetan Reichardt: LAAO vs. OAC in AF – Balancing Nonprocedural Bleeding and Ischemic Stroke Risk
-
Nov 17, 2026, 23:42Brian Tegtmeyer: Expanding Pre-Hospital Administration of Low-Titer O Positive Whole Blood
-
Nov 17, 2026, 23:41Mansi Kala: Advancing Hematology – From Evidence to Clinical Excellence
-
Nov 17, 2026, 23:40Nathan Connell: Registered for the WFH Comprehensive Care Summit 2027 in Prague
-
Nov 17, 2026, 23:38Yaariv Khaykin: Does Reducing AF Burden After Ablation Change the Need for Anticoagulation?